Treatment Guideline: Adjuvant Olaparib for BRCA1/2 Variant Carriers - Updated in 2026

The Breast Oncology Center at Dana-Farber Cancer Institute held multidisciplinary meetings to discuss recommendations for the use of adjuvant olaparib for high-risk, breast cancer in BRCA1/2 carriers.